文献速递临床试验与 GCP基础与转化研究

自体多抗原靶向T细胞疗法治疗胰腺癌:一项1/2期试验

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.
PubMed 文献 · Nat Med · 2026-01-02

该1/2期试验将体外扩增、靶向PRAME、SSX2、MAGEA4、Survivin和NY-ESO-1五种肿瘤相关抗原的辅助性T细胞1极化多克隆自体非工程T细胞产品,按每月1×10^7个细胞每平方米输注给晚期胰腺导管腺癌患者(A组为一线化疗应答者13例,B组为化疗难治者12例,C组为可切除者12例)。56例采集者中37例完成输注,仅1例治疗相关严重不良事件;A组和B组疾病控制率分别为84.6%(95%CI 54.6-98.1%)和25%(95%CI 5.5-57.2%),C组9例切除者中2例随访66个月无病。

要点

  • 每月输注1×10^7个细胞每平方米的自体多抗原靶向T细胞产品,56例中37例完成输注,仅1例治疗相关严重不良事件。
  • A组(化疗应答)疾病控制率84.6%(95%CI 54.6-98.1%),B组(化疗难治)为25%(95%CI 5.5-57.2%)。
  • C组9例切除者中2例随访66个月无病;输注细胞持续存在至治疗后12个月。

核心结论

  • 作者认为,该自体多抗原靶向T细胞疗法值得进一步研究,可单用或与其他互补疗法联合。

研究设计与样本

  • 1/2期试验,体外扩增、辅助性T细胞1极化的多克隆自体非工程T细胞产品,靶向PRAME、SSX2、MAGEA4、Survivin和NY-ESO-1五种肿瘤相关抗原。
  • 每月输注1×10^7个细胞每平方米,A组为一线化疗应答的晚期胰腺导管腺癌13例,B组为化疗难治的晚期胰腺导管腺癌12例,C组为可切除胰腺导管腺癌12例。
  • 56例参与者采集细胞,37例完成输注;主要终点为安全性和完成六次输注的可行性。

主要发现

  • 仅1例治疗相关严重不良事件。
  • A组疾病控制率84.6%(95%CI 54.6-98.1%),B组25%(95%CI 5.5-57.2%)。
  • C组9例切除参与者中2例随访66个月无病。
  • 输注细胞持续存在至治疗后12个月;应答者相比无应答者,在给药期间(P=0.027)和随访中检测到肿瘤定向T细胞水平升高。
  • 临床结局与外周功能性肿瘤相关抗原靶向T细胞克隆扩增及治疗中出现抗原扩展相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T cell therapy has proven challenging for pancreatic ductal adenocarcinoma (PDAC), partly due to heterogeneous expression of tumor-associated antigens (TAAs). To address tumor heterogeneity and mitigate immune evasion, an ex vivo expanded, polyclonal, T helper 1 cell-polarized T cell product targeting five TAAs-PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1-was developed. These antigens were chosen based on their tumor specificity, oncogenicity, immunogenicity and level of expression. In a phase 1/2 trial, this autologous nonengineered T cell product was administered (1 × 107 cells m-2 per infusion) monthly to patients with advanced PDAC responding (arm A, n = 13) or refractory (arm B, n = 12) to first-line chemotherapy or with resectable disease (arm C, n = 12). Primary endpoints were safety and feasibility of completing six infusions, whereas exploratory efficacy endpoints included persistence and evaluating the relationship between clinical benefit and the expansion of the infused effector T cells, as well as the induction of de novo immune responses. Of 56 participants procured, 37 were infused, with only 1 treatment-related serious adverse event. Disease control rates in arms A and B were 84.6% (95% confidence interval: 54.6-98.1%) and 25% (95% confidence interval: 5.5-57.2%), respectively. In arm C, two of nine resected participants remained disease free after 66 months of follow-up. The infused cells persisted up to 12 months posttreatment and elevated levels of tumor-directed T cells were detected during dosing (P = 0.027) and follow-up in responders compared to nonresponders. Clinical outcomes correlated with peripheral expansion of functional TAA-targeted T cell clones and treatment-emergent antigen spreading. Thus, further investigation of this approach, either as a single agent or combined with other complementary modalities, is warranted (ClinicalTrials.gov identifier: NCT03192462 ).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Musher BL, Vasileiou S, Smaglo BG, et al. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026. PMID: 41482561. doi:10.1038/s41591-025-04043-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。